Clinical Trial of Potential CAR T-cell Therapy for Advanced Multiple Myeloma to Open in US
Janssen recently initiated a Phase 1b/2 clinical development program to evaluate JNJ-68284528, a chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment  of…